Format

Send to

Choose Destination
Medicines (Basel). 2018 Oct 2;5(4). pii: E107. doi: 10.3390/medicines5040107.

New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders.

Author information

1
Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy. mscherma@unica.it.
2
Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy. paolo.masia@unica.it.
3
Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy. matteo.deidda@unica.it.
4
Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy. wfratta@unica.it.
5
Medication Development program, NIDA-IRP, NIH/DHHS, NIDA suite 3301, Baltimore, MD 21224, USA. gtanda@intra.nida.nih.gov.
6
Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy. pfadda@unica.it.
7
Centre of Excellence "Neurobiology of Dependence", University of Cagliari, 09042 Monserrato, Italy. pfadda@unica.it.
8
CNR Institute of Neuroscience ⁻ Cagliari, National Research Council, 09042 Monserrato, Italy. pfadda@unica.it.
9
National Institute of Neuroscience (INN), University of Cagliari, 09042 Monserrato, Italy. pfadda@unica.it.

Abstract

Following the discovery of the endocannabinoid system and its potential as a therapeutic target for various pathological conditions, growing interest led researchers to investigate the role of cannabis and its derivatives for medical purposes. The compounds Δ9-tetrahydrocannabinol and cannabidiol are the most abundant phytocannabinoids found in cannabis extracts, as well as the most studied. The present review aims to provide an overview of the current evidence for their beneficial effects in treating psychiatric disorders, including schizophrenia, anxiety, and depression. Nevertheless, further investigations are required to clarify many pending issues, especially those relative to the assessment of benefits and risks when using cannabis for therapeutic purposes, thereby also helping national and federal jurisdictions to remain updated.

KEYWORDS:

cannabidiol; phytocannabinoids; psychiatric disorders; Δ9-tetrahydrocannabinol

PMID:
30279403
DOI:
10.3390/medicines5040107
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center